Reply to Letter to the Editor: "What Is the Optimal Antiplatelet Therapy in Type 2 Diabetes Mellitus Patients with Small Diameter Stents?".
作者信息
Algazzar Alaa S, Aljondi Raghad M, Metwalli Eilaf Majdi, Dhaher Ghazal Y, Mushaeb Hanan H, Aljadani Renad H, Balahmar Rahaf S, Hafiz Awatif, Qutub Mohamed A
机构信息
Department of Cardiology, Ahmed Maher Teaching Hospital, Cairo, Egypt.
Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
出版信息
Anatol J Cardiol. 2025 Jun 30;29(8):450-1. doi: 10.14744/AnatolJCardiol.2025.5348.
Abstract
摘要
相似文献
1
Reply to Letter to the Editor: "What Is the Optimal Antiplatelet Therapy in Type 2 Diabetes Mellitus Patients with Small Diameter Stents?".致编辑信件的回复：“2型糖尿病合并小直径支架患者的最佳抗血小板治疗方案是什么？”
Anatol J Cardiol. 2025 Jun 30;29(8):450-1. doi: 10.14744/AnatolJCardiol.2025.5348.
2
What is the Optimal Antiplatelet Therapy in Type 2 Diabetes Mellitus Patients with Small Diameter Stents?小直径支架的2型糖尿病患者的最佳抗血小板治疗方案是什么？
Anatol J Cardiol. 2025 May 26;29(8):448-9. doi: 10.14744/AnatolJCardiol.2025.5347.
3
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.双联抗血小板治疗的疗程：针对2016年美国心脏病学会/美国心脏协会关于冠心病患者双联抗血小板治疗疗程重点更新指南的系统评价：美国心脏病学会/美国心脏协会临床实践指南工作组报告
Circulation. 2016 Sep 6;134(10):e156-78. doi: 10.1161/CIR.0000000000000405. Epub 2016 Mar 29.
4
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.双联抗血小板治疗时间：2016 年 ACC/AHA 指南双联抗血小板治疗时间的聚焦更新：冠心病患者双联抗血小板治疗时间的临床实践指南——美国心脏病学会/美国心脏协会工作组报告。
J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39. doi: 10.1016/j.jacc.2016.03.512. Epub 2016 Mar 29.
5
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.冠状动脉支架植入术后2型糖尿病患者三联抗血小板治疗与双联抗血小板治疗的有效性和安全性比较：一项随机对照试验的系统评价和荟萃分析
BMC Cardiovasc Disord. 2015 Oct 9;15:118. doi: 10.1186/s12872-015-0114-1.
6
Indobufen versus aspirin after percutaneous coronary intervention in elderly patients with acute coronary syndrome.吲哚布芬与阿司匹林用于老年急性冠状动脉综合征患者经皮冠状动脉介入治疗后的比较
BMC Cardiovasc Disord. 2025 Jul 7;25(1):495. doi: 10.1186/s12872-025-04843-0.
7
Evaluation of the NHS England Low-Calorie Diet implementation pilot: a coproduced mixed-method study.英国国家医疗服务体系（NHS）低热量饮食实施试点评估：一项联合开展的混合方法研究。
Health Soc Care Deliv Res. 2025 Jul;13(29):1-63. doi: 10.3310/MPRT2139.
8
Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.冠状动脉支架治疗缺血性心脏病：一项快速系统评价
Health Technol Assess. 2000;4(23):1-153.
9
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.糖尿病患者与非糖尿病患者使用药物洗脱支架和裸金属支架的疗效比较：协作网络荟萃分析
BMJ. 2008 Aug 29;337:a1331. doi: 10.1136/bmj.a1331.
10
Pharmacodynamic effects of early aspirin withdrawal after percutaneous coronary intervention in patients with atrial fibrillation treated with ticagrelor or prasugrel.替格瑞洛或普拉格雷治疗的房颤患者经皮冠状动脉介入治疗后早期停用阿司匹林的药效学效应
Platelets. 2025 Dec;36(1):2507037. doi: 10.1080/09537104.2025.2507037. Epub 2025 May 23.
本文引用的文献
1
What is the Optimal Antiplatelet Therapy in Type 2 Diabetes Mellitus Patients with Small Diameter Stents?小直径支架的2型糖尿病患者的最佳抗血小板治疗方案是什么？
Anatol J Cardiol. 2025 May 26;29(8):448-9. doi: 10.14744/AnatolJCardiol.2025.5347.
2
Comparison of 1-Year Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Type 2 Diabetes Patients After Implantation of Small Diameter Stents.替格瑞洛与氯吡格雷在小直径支架植入术后2型糖尿病患者中1年临床结局的比较
Anatol J Cardiol. 2025 Jan 7;29(2):95-103. doi: 10.14744/AnatolJCardiol.2024.4603.
3
Effect of ticagrelor versus clopidogrel after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome-propensity score matching analysis.急性冠脉综合征患者行血管内超声或血管造影指导的药物洗脱支架置入术后替格瑞洛与氯吡格雷的疗效：倾向评分匹配分析。
BMC Cardiovasc Disord. 2024 Jan 18;24(1):58. doi: 10.1186/s12872-023-03659-0.
4
Clinical implication of ticagrelor monotherapy in patients with small vessel coronary artery disease: results from the TICO randomized trial.替格瑞洛单药治疗对小血管冠状动脉疾病患者的临床意义：TICO随机试验结果
Front Cardiovasc Med. 2023 Aug 8;10:1237826. doi: 10.3389/fcvm.2023.1237826. eCollection 2023.
5
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.氯吡格雷与替格瑞洛或普拉格雷在 70 岁或以上非 ST 段抬高型急性冠脉综合征患者中的比较（POPular AGE）：随机、开放标签、非劣效性试验。
Lancet. 2020 Apr 25;395(10233):1374-1381. doi: 10.1016/S0140-6736(20)30325-1.
6
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.替格瑞洛与氯吡格雷治疗急性冠脉综合征患者的支架血栓形成：来自前瞻性、随机 PLATO 试验的分析。
Circulation. 2013 Sep 3;128(10):1055-65. doi: 10.1161/CIRCULATIONAHA.113.002589. Epub 2013 Jul 30.
7
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.替格瑞洛与氯吡格雷在急性冠脉综合征合并糖尿病患者中的疗效比较：来自 PLATelet inhibition and patient Outcomes (PLATO) 研究的亚组分析。
Eur Heart J. 2010 Dec;31(24):3006-16. doi: 10.1093/eurheartj/ehq325. Epub 2010 Aug 29.
8
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.替格瑞洛与氯吡格雷用于急性冠脉综合征患者的比较
N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.
9
Prasugrel versus clopidogrel in patients with acute coronary syndromes.普拉格雷与氯吡格雷用于急性冠状动脉综合征患者的比较。
N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4.
Zotero 插件